Giorgia Guglielmi
Giorgia Guglielmi is a freelance science writer based in Basel, Switzerland. Specializing in life sciences, medicine, and the relationship between science and society, she has published numerous articles in outlets including Nature, Science, and Scientific American. She holds a PhD in biology from the European Molecular Biology Laboratory and a Master’s in Science Writing from the Massachusetts Institute of Technology. She has received recognition for her work, including the John Kendrew Award in 2020 and an ERC-funded FRONTIERS Media Fellowship in 2025. She has also led lectures and workshops on science communication at institutions such as Harvard University and the University of Zurich.
Researchers have developed a new technique that can identify which gut microbes have migrated from the gut to the blood.
A recent study shows that some bacterial strains are similar to the human host phylogeny, suggesting that they evolved alongside humans.
The findings of a new study suggest that Bacteroides can metabolize cholesterol, thus helping to regulate its levels in the blood.
COVID-19 alters the local immunity of the lung in ways that weaken the body’s antimicrobial defense and facilitate the development of secondary infections.
The findings of a recent study suggest that phages can be used to treat IBD and other diseases associated with gut microbes.
The findings of a recent study suggest that engineered native gut bacteria could be employed to help treat certain diseases such as diabetes.
A recent study suggests that the microbiome changes in response to human consumption of non-nutritive sweetener may induce glycemic changes in consumers in a personalized manner.
Antimicrobial resistant bacteria are present in newborns after just a few hours of life and they help to understand the routes of transmission of antibiotic-resistance genes.
The findings of a new research suggest that different responses to statins can be explained by the variation in the human microbiota.
The findings of a new research illuminate the link between IBS and gut bacteria, and suggest that histamine is a good target for therapies against the condition.
